First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review

Basic and Clinical Pharmacology and Toxicology

Volumn 118, Issue 1, 2016, Pages 32-36

  Lassen, Dorte ^a   Ennis, Zandra Nymand ^a,b   Damkier, Per ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; VENLAFAXINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

COHORT ANALYSIS; CONGENITAL MALFORMATION; FIRST TRIMESTER PREGNANCY; HUMAN; LIVE BIRTH; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW (TOPIC); ABNORMALITIES, DRUG-INDUCED; CHEMICALLY INDUCED; DEPRESSIVE DISORDER, MAJOR; FEMALE; PREGNANCY; PRENATAL EXPOSURE;

ABNORMALITIES, DRUG-INDUCED; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; DULOXETINE HYDROCHLORIDE; FEMALE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS; VENLAFAXINE HYDROCHLORIDE;

EID: 84983120368     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12497     Document Type: Review

References (37)

1. Nordeng H, van Gelder MMHJ, Spigset O, Koren G, Einarson A, Eberhard-Gran M. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012;32:186-94.
2. Lefkovics E, Baji I, Rigó J. Impact of maternal depression on pregnancies and on early attachment. Infant Ment Health J 2014;35:354-65.
3. Jimenez-Solem E. Exposure to antidepressants during pregnancy-prevalences and outcomes. Dan Med J 2014;61:B4916.
4. Chaudron LH. Complex challenges in treating depression during pregnancy. Am J Psychiatry 2013;170:12-20.
5. Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis C-L et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013;74:e293-308.
6. Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 2013;70:436-43.
7. Wang S, Yang L, Wang L, Gao L, Xu B, Xiong Y. Selective serotonin reuptake inhibitors (SSRIs) and the risk of congenital heart defects: a meta-analysis of prospective cohort studies. J Am Heart Assoc 2015;4:1-5.
8. Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014;370:2397-407.
9. Payne JL. Antidepressant exposure during the first trimester does not increase the risk of cardiac malformations in infants. Evid Based Ment Health 2015;18:48.
10. Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 2015;350:h1798.
11. Andrade C. The safety of duloxetine during pregnancy and lactation. J Clin Psychiatry 2014;75:e1423-7.
12. Antenatal and postnatal mental health: clinical management and service guidance | 1-recommendations | Guidance and guidelines | NICE [Internet]. http://www.nice.org.uk/guidance/cg192/chapter/1-recommendations#treating-specific-mental-health-problems-in-pregnancy-and-the-postnatal-period (last accessed on 7 June 2015).
13. Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015;29:459-525.
14. Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller H-J et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry 2015;16:76-95.
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W-65.
16. Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry Rev Can Psychiatr 2009;54:242-6.
17. Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E, Kalyoncu NI et al. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol 2004;19:235-8.
18. Boyce PM, Hackett LP, Ilett KF. Duloxetine transfer across the placenta during pregnancy and into milk during lactation. Arch Womens Ment Health 2011;14:169-72.
19. Abdy NA, Gerhart K. Duloxetine withdrawal syndrome in a newborn. Clin Pediatr (Phila) 2013;52:976-7.
20. Bellantuono C, Marini A, Lucarelli C. Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine. Clin Drug Investig 2013;33:685-8.
21. Eyal R, Yaeger D. Poor neonatal adaptation after in utero exposure to duloxetine. Am J Psychiatry 2008;165:651.
22. Briggs GG, Ambrose PJ, Ilett KF, Hackett LP, Nageotte MP, Padilla G. Use of duloxetine in pregnancy and lactation. Ann Pharmacother 2009;43:1898-902.
23. Manakova E, Hubickova L. Antidepressant drug exposure during pregnancy. CZTIS small prospective study. Neuro Endocrinol Lett 2011;32(Suppl 1):53-6.
24. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83:68-76.
25. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-30.
26. Einarson A, Smart K, Vial T, Diav-Citrin O, Yates L, Stephens S et al. Rates of major malformations in infants following exposure to duloxetine during pregnancy: a preliminary report. J Clin Psychiatry 2012;73:1471.
27. Hoog SL, Cheng Y, Elpers J, Dowsett SA. Duloxetine and pregnancy outcomes: safety surveillance findings. Int J Med Sci 2013;10:413-9.
28. Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005;20:327-41.
29. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals 2013;6:1221-86.
30. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106:86-94.
31. Schaefer C, Peters P, Millers R. Drugs During Pregnancy and Lactation, Treatment Options and Risk Assessment, 3rd edn. Academic Press, Elsevier, 2014.
32. Schardein J. Chemically Induced Birth Defects, 3rd edn. Marcel Dekker INC, New York, 2000.
33. EUROCAT guide 1.3 and reference documents 2014 [Internet]. http://www.eurocat-network.eu/ (last accessed on 10 August 2015).
34. Bellantuono C, Vargas M, Mandarelli G, Nardi B, Martini MG. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Hum Psychopharmacol 2015;30:143-51.
35. European Medicines Agency - Guideline on risk assessment of medical products on human Reproduction and lactation: from data to labelling. [Internet]. http://www.ema.europa.eu/ema/ (last accessed on 10 August 2015).
36. Summary of Product Characteristics [Internet]. http://www.produktresume.dk/docushare/dsweb/View/Collection-10 (last accessed on 10 August 2015).
37. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, Afzal S et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012;2:1-9.